- Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD”) Type 2a meeting with the FDA in the second half of 2025 - ...

Scientists have developed a revolutionary AI "fingerprint" technology that can accurately show how cancer cells respond to ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...

Four Goldman Sachs stock picks make sense for growth and income investors charting a course for the rest of what could be a ...

LXP is a $2.7 billion REIT in the industrial sector. The company's focus is on buying, developing and operating high-quality, ...

SO YES, WE STILL NEED TO BE TAKING IT SERIOUSLY. The federal government program that provides free at-home COVID-19 tests says it is "not currently accepting orders," according to the ...

“The man's family, who was there, agreed to the procedure, and they also said that I could stay and photograph as EMTs worked to save his life,” said John Moore, a Getty Images photographe ...

The U.S. stock market's sell-off is worsening Monday, and it's heading toward its worst day since 2022 as Wall Street questions how much pain President Donald Trump is willing for the economy to ...

The stock finally dropped into free fall today, plunging more than 15 percent to mark one of the company’s worst trading days since it went public in 2010. The tumble erased the last vestiges of ...

Sarfaraz Niazi, PhD, urges the FDA to let the USPharmacopeia (USP) create product release specifications for biosimilars to cut costs, speed development, and enhance accessibility. My citizen ...